Variables associated with response to cell therapy
| Variable . | Response . | P . | |||
|---|---|---|---|---|---|
| Patients, n . | CR/SD/PR . | PD . | NE . | ||
| Overall association of number of sites involved and response (n = 49) | |||||
| 1 site | 14 | 14 (100%) | 0 (0%) | 0 (0%) | .01, .01* |
| 2 sites | 21 | 13 (60%) | 4 (20%) | 4 (20%) | |
| 3+ sites | 14 | 7 (50%) | 6 (50%) | 1 (0%) | |
| Overall association of rituximab use and response to cell therapy (n = 49) | |||||
| Patients failing Rituxan | 19 | 11 (58%) | 7 (37%) | 1 (5%) | .07, .06* |
| Patient w/o prior Rituxan or in PR after Rituxan | 30 | 23 (77%) | 3 (11%) | 4 (11%) | |
| Overall association of rituximab use and response (n = 49) | |||||
| Patients failing Rituxan by treatment | 19 | 11 | 7 | 1 | |
| DLI | 9 | 4 (44%) | 4 (44%) | 1 (11%) | .47, .63* |
| EBV-CTL | 10 | 7 (70%) | 3 (30%) | 0 (0%) | |
| Patients without prior Rituxan or in PR after Rituxan by treatment | 30 | 23 | 3 | 4 | |
| DLI | 21 | 17 (82%) | 1 (6%) | 3 (12%) | .32, .22* |
| EBV CTL | 9 | 6 (67%) | 2 (22%) | 1 (11%) | |
| Overall association of steroid use and response (n = 45) | |||||
| No steroid use | 40 | 29 (72%) | 8 (20%) | 3 (7%) | .85, .99* |
| Steroid use | 9 | 6 (66%) | 2 (22%) | 1 (11%) | |
| Overall association of use of steroids and/or cyclosporine or sirolimus (n = 49) | |||||
| No steroid use | 35 | 26 | 6 | 3 | .76, .44* |
| Steroid use | 14 | 9 | 4 | 1 | |
| Variable . | Response . | P . | |||
|---|---|---|---|---|---|
| Patients, n . | CR/SD/PR . | PD . | NE . | ||
| Overall association of number of sites involved and response (n = 49) | |||||
| 1 site | 14 | 14 (100%) | 0 (0%) | 0 (0%) | .01, .01* |
| 2 sites | 21 | 13 (60%) | 4 (20%) | 4 (20%) | |
| 3+ sites | 14 | 7 (50%) | 6 (50%) | 1 (0%) | |
| Overall association of rituximab use and response to cell therapy (n = 49) | |||||
| Patients failing Rituxan | 19 | 11 (58%) | 7 (37%) | 1 (5%) | .07, .06* |
| Patient w/o prior Rituxan or in PR after Rituxan | 30 | 23 (77%) | 3 (11%) | 4 (11%) | |
| Overall association of rituximab use and response (n = 49) | |||||
| Patients failing Rituxan by treatment | 19 | 11 | 7 | 1 | |
| DLI | 9 | 4 (44%) | 4 (44%) | 1 (11%) | .47, .63* |
| EBV-CTL | 10 | 7 (70%) | 3 (30%) | 0 (0%) | |
| Patients without prior Rituxan or in PR after Rituxan by treatment | 30 | 23 | 3 | 4 | |
| DLI | 21 | 17 (82%) | 1 (6%) | 3 (12%) | .32, .22* |
| EBV CTL | 9 | 6 (67%) | 2 (22%) | 1 (11%) | |
| Overall association of steroid use and response (n = 45) | |||||
| No steroid use | 40 | 29 (72%) | 8 (20%) | 3 (7%) | .85, .99* |
| Steroid use | 9 | 6 (66%) | 2 (22%) | 1 (11%) | |
| Overall association of use of steroids and/or cyclosporine or sirolimus (n = 49) | |||||
| No steroid use | 35 | 26 | 6 | 3 | .76, .44* |
| Steroid use | 14 | 9 | 4 | 1 | |
NE indicates not evaluated (patients dying within 8 days of initiated T-cell infusion who were not evaluated for response to T-cell therapy).
P excluding patients who were not evaluable; numbers in parentheses are raw percentages.